U.S. Adenomyosis Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: U.S.
- ✓Market: Adenomyosis Market
- ✓Market Size 2024: USD 1.18 billion
- ✓Market Size 2032: USD 2.09 billion
- ✓CAGR: 7.4%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Payer Coverage Early: Device manufacturers should file an adenomyosis PMA supplement with FDA by December 2026 and pair it with a CMS TCET application. Investors should prioritize evidence-backed MRgFUS platforms before MDUFA VI reauthorization concludes in 2027.
Adenomyosis Care in the United States: Market Overview
The U.S. adenomyosis market generated an estimated USD 1.18 billion in 2024 across branded pharmaceuticals, medical devices, and surgical procedures, based on analyst estimates reconciled against CMS fee schedule volumes and manufacturer disclosures. No therapy carries an FDA-approved adenomyosis indication, so revenue concentrates in adjacent labels: AbbVie's Orilissa for endometriosis pain, Sumitomo Pharma's Myfembree for heavy menstrual bleeding, and Bayer's Mirena for heavy menstrual bleeding.
Government has been the dominant force in shaping how this market is structured. The Centers for Medicare and Medicaid Services sets economics through the Medicare Physician Fee Schedule and the Hospital Outpatient Prospective Payment System, determining whether MRgFUS and uterine-sparing procedures are financially viable. The private sector has led on innovation: InSightec's Exablate system, cleared by FDA for uterine fibroids, and Intuitive Surgical's da Vinci platform have driven procedural adoption wherever payer policy permits.
Policy-Driven Growth in American Adenomyosis Care
Section 2713 of the Public Health Service Act, added by the Patient Protection and Affordable Care Act, requires non-grandfathered private health plans to cover FDA-approved contraceptive methods without cost sharing, following HRSA Women's Preventive Services Guidelines. Levonorgestrel intrauterine systems, including Mirena, qualify, and Mirena's FDA-approved heavy menstrual bleeding indication lets clinicians position it as first-line symptom management for adenomyosis. Zero cost-sharing removes the largest patient barrier, lifting LNG-IUS uptake across commercial and Medicaid populations.
The Centers for Medicare and Medicaid Services' New Technology Add-on Payment program, governed by Section 1886(d)(5)(K) of the Social Security Act, pays hospitals an additional 50 to 65 percent of qualifying device cost for inpatient technologies. The Transitional Coverage for Emerging Technologies pathway, finalized in 2024, extends a parallel route for breakthrough devices. Together these mechanisms reduce hospital capital risk for MRgFUS suites, accelerating installation in academic medical centers and driving procedure volumes.
Regulatory Barriers and Compliance Costs
FDA regulates adenomyosis therapies under the Federal Food, Drug, and Cosmetic Act, and promotion of GnRH antagonists or LNG-IUS for adenomyosis falls outside approved labeling restricted under 21 CFR 202.1. Sponsors pursuing a dedicated indication must run investigational new drug studies under 21 CFR Part 312, while class III ablation devices require premarket approval under 21 CFR Part 814 with an FDA review goal of 180 days under MDUFA V. Pivotal trials for a new adenomyosis label typically cost USD 40 to 80 million and require three to five years.
State certificate-of-need laws administered by state health departments, such as New York's Public Health Law Article 28 review, can delay installation of MRgFUS or outpatient surgical suites by six to 12 months. Hospital Price Transparency rules under 45 CFR Part 180 require posting of negotiated rates, and Open Payments reporting under Section 1128G of the Social Security Act requires manufacturers to disclose physician payments. Compliance adds administrative cost that smaller device firms struggle to absorb.
Policy-Created Opportunities in U.S. Adenomyosis Care
The TCET pathway, capped at five technologies per year, creates a fast route for breakthrough-designated MRgFUS and minimally invasive ablation devices addressing adenomyosis. Manufacturers holding Breakthrough Device designation under Section 515B of the Federal Food, Drug, and Cosmetic Act can apply for TCET coverage once FDA authorization is granted. Hospital systems that install these platforms before the first TCET decisions will capture early referral volume from patients seeking uterine-sparing treatment.
Medicare Drug Price Negotiation under the Inflation Reduction Act creates a defined commercial window for novel oral adenomyosis therapies. Small molecules become eligible for selection seven years after approval, with negotiated prices effective nine years after approval, compared with 11 and 13 years for biologics. Oral GnRH antagonist developers should structure development timelines around that nine-year horizon to protect launch economics.
Regulatory and Policy Environment
The primary legislation governing adenomyosis products is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by the Food and Drug Administration through its Center for Drug Evaluation and Research and Center for Devices and Radiological Health. Medical devices must comply with the Quality Management System Regulation at 21 CFR Part 820, which takes effect February 2, 2026 and aligns U.S. requirements with ISO 13485:2016. Reimbursement falls under Title XVIII of the Social Security Act, administered by CMS, while the Physician Payments Sunshine Act requires manufacturer Open Payments disclosures.
Key upcoming changes include the third Medicare Drug Price Negotiation cycle, with selected drugs announced by February 1, 2026 and negotiated prices effective January 1, 2028, and reauthorization of MDUFA V, which expires September 30, 2027. Compared with the European Union, where Regulation (EU) 2017/745 on medical devices has extended transitional deadlines into 2027 and 2028, the U.S. PMA process offers a defined 180-day review goal but no centralized reimbursement decision. CMS coverage pathways such as TCET attempt to close that gap.
Long-Term Policy Outlook for U.S. Adenomyosis Care
Between 2026 and 2032, MDUFA VI negotiations will determine FDA review resourcing for adenomyosis device submissions, and the QMSR transition will raise audit requirements for smaller manufacturers. The Medicare Drug Price Negotiation Program extends to Part B drugs from 2028, applying to physician-administered GnRH products such as leuprolide, which clinicians use off-label in adenomyosis. Both changes move pricing pressure onto branded hormonal agents.
These changes will reshape the market by shifting revenue from high-priced branded hormonal agents toward lower-cost generics and outpatient procedures. Payers will reward uterine-sparing care that avoids hysterectomy, and CMS payment rules will favor ambulatory MRgFUS delivery. By 2032, the U.S. adenomyosis market should reach USD 2.09 billion as TCET-backed devices and price-negotiated oral therapies capture share.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 1.18 billion |
| Market Size 2032 | USD 2.09 billion |
| Growth Rate (CAGR) | 7.4% |
| Most Critical Decision Factor | Payer coverage of off-label GnRH and hysterectomy alternatives |
| Largest Region | Northeast |
| Competitive Structure | Fragmented; pharmaceutical incumbents and device specialists |
Leading Market Participants
- AbbVie
- Sumitomo Pharma
- Bayer
- Organon
- InSightec
- Hologic
- Intuitive Surgical
- Johnson & Johnson
- Medtronic
- Teva Pharmaceuticals
Frequently Asked Questions
Market Segmentation
- Hormonal Therapy
- Levonorgestrel Intrauterine Systems
- Uterine-Sparing Procedures
- Hysterectomy
- Hospitals
- Ambulatory Surgical Centers
- Gynecology Clinics
- Academic Medical Centers
- Medicare
- Medicaid
- Commercial Insurance
- Out-of-Pocket
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.